Picture of VGI Health Technology logo

VTL VGI Health Technology Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+2.59%
3m+1.68%
6m+1.99%
1yr-69.23%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-1403614.29%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202030th Jun 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2020 / 2021

Blurred out image of VGI Health Technology EPS forecast chart

Profile Summary

VGI Health Technology Limited develops and commercializes a range of health and therapeutic products and technologies. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines, including nE1-Heart and nE1-Elite. nE1-Heart product is targeting maintenance of heart health tocotrienols have a similar mode of action as statins. nE1-Elite product reduces delayed onset muscle soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power. Its technologies include MELT3, TransT3 and Tocotrienol ProDrugs (TPD). MELT3 is designed for nutraceuticals and dietary supplements. TransT3 and TPD platforms are non-invasive delivery methods for T3s designed to bypass digestion in the gut and metabolism in the liver and delivering T3s into the blood stream without the use of invasive techniques such as needles and surgical implants.

Directors

Last Annual
June 30th, 2019
Last Interim
December 31st, 2019
Incorporated
September 22nd, 2004
Public Since
June 27th, 2007
No. of Shareholders
3,805
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconNational Stock Exchange of Australia
Shares in Issue
179,998,454

VTL Share Price Performance

Upcoming Events for VTL

Similar to VTL

Picture of IQX logo

IQX

au flag iconNational Stock Exchange of Australia

FAQ

Or unlock with your email

Or unlock with your email